Suchergebnisse - "Matous, Jeffrey V"

PubPharm (36)

1

Publisher Correction : Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

enthalten in: Nature medicine | 2023

von Mailankody, S. | Matous, J. | Chhabra, S. | +15

ErratumFor: Nat Med. 2023 Feb;29(2):422-429. - PMID 36690811

2

BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia

enthalten in: Hematology/oncology clinics of North America | 2023

von Varettoni, M. | Matous, J.

3

Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

enthalten in: Seminars in hematology | 2023

von Buske, C. | Castillo, J. | Abeykoon, J. | +25

4

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma : phase 1 UNIVERSAL trial interim results

enthalten in: Nature medicine | 2023

von Mailankody, S. | Matous, J. | Chhabra, S. | +15

CommentIn: Nat Med. 2023 Feb;29(2):303-304. - PMID 36690813

5

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia : Final Analysis From the Randomized Phase III iNNOVATE Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Buske, C. | Tedeschi, A. | Trotman, J. | +17

CommentIn: Future Oncol. 2023 Feb;19(5):345-353. - PMID 36815271

6

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia : Final Analysis of the Substudy of the Phase III InnovateTM Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Trotman, J. | Buske, C. | Tedeschi, A. | +11

7

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma : Final analysis of second dose-expansion cohort

enthalten in: American journal of hematology | 2021

von Berdeja, J. | Gregory, T. | Faber, E. | +5

8

A phase I/ II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma : Final analysis of second dose‐expansion cohort

enthalten in: American Journal of Hematology | 2021

von Berdeja, J. | Gregory, T. | Faber, E. | +5

9

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia : the ASPEN study

enthalten in: Blood | 2020

von Tam, C. | Opat, S. | D'Sa, S. | +30

10

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

enthalten in: Hematological oncology | 2020

von Chari, A. | Cornell, R. | Gasparetto, C. | +14